Chris Viehbacher appointed Sanofi-Aventis CEO

Share this article:
Chris Viehbacher
Chris Viehbacher
Sanofi-Aventis announced September 10 that Chris Viehbacher will succeed Gerard Le Fur as the company's CEO, effective December 1, 2008. 

The announcement came two days after Viehbacher resigned his postion on GlaxoSmithKline's board, with plans to leave the company entirely. Viehbacher will remain executive director and president at GSK until December 1.

Viehbacher, also a PhRMA board member, was a contender for the CEO position at GSK following the retirement of Jean-Pierre Garnier last May. Andrew Witty, currently the CEO at GSK, secured that postion.

According to a statement from the Sanofi board of directors, Le Fur will stay on at Sanofi after Viehbacher becomes CEO, and will "provide his competences to the general management of the group in the scientific domain." The financial conditions of Viehbacher's hiring will be posted online in the coming days, according to the Sanofi statement. 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...